MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

FAB-Fidia Advanced Biopolymers

FAB-Fidia Advanced Biopolymers
The core technology of FAB is based on a new class of patented biopolymers obtained from chemical modifications of hyaluronan

The company in detail

Profile

Fidia Advanced Biopolymers (FAB) is a wholly-owned subsidiary of Fidia Farmaceutici S.p.A., a private Italian pharmaceutical company founded in 1946 and a world leader in hyaluronan technology. The company headquarters are located in Abano Terme, about 50 kilometres west of Venice

FAB was established in 1992 and is a fully-integrated company with R&D, manufacturing, marketing and sales divisions. Its mission is to provide the medical community with innovative therapeutic tools for the regeneration of connective and structural tissues damaged by injuries, aging or degenerative diseases.

FAB emerged as the pioneer in the field of autologous tissue transplants. It is has been providing for almost ten years the production of autologous dermal, epidermal and cartilage grafts in an ISO 9002 certified facility dedicated to tissue engineering, currently the largest in Europe. FAB has received GMP approval for manufacturing of tissue-engineered products according to the new European regulations in December 2006.

The core technology of FAB is based on a new class of patented biopolymers obtained from chemical modifications of hyaluronan, a naturally occurring polysaccharide ubiquitous and very conserved in living species. FAB develops, manufactures and markets innovative medical devices based on this technology and expressly tailored for its three business areas: 1) Bio-orthopedics; 2) Bio-surgery; 3) Soft tissue repair.

FAB actively promotes its own proprietary products and services with a network of product specialists in Italy. FAB has a keen interest in expanding its opportunities by licensing its proprietary products either on a multinational level or on a country-by-country basis.

For more information about FAB please contact Dr. Alessandro Di Martino, Manager of International Markets, at the above email address

Out-licensing

Hyaluronan based gel for prevention and reduction of adhesion formation in the abdominal pelvic area More
Hyaluronan based gel for prevention and reduction of adhesion formation in tendon and nerve surgery More
Hyaluronan based matrix to manage severe burns and full-thickness wounds More

Deals

To view this information, you must subscribe to PL Intelligence.

Contact details

Mr Alessandro Di Martino
Head Manager
International Markets

Contact directly

Head office

FAB-Fidia Advanced Biopolymers
Via Ponte della Fabbrica, 3/B
Abano Terme
35031
Italy

Company figures

Formed: 1992

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us